首页|Emerging Proteolysis Targeting Antibodies (PROTABs) for Application in Cancer Therapy
Emerging Proteolysis Targeting Antibodies (PROTABs) for Application in Cancer Therapy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
? 2022 American Chemical Society. All rights reserved.The emerging proteolysis targeting antibodies (PROTABs) offer an attractive technology that circumvents some of the challenges of small-molecule intracellular degraders with limited bioavailability and cell permeability. PROTABs present an improved approach to target degradation of membrane-bound and cell surface proteins and use multispecific binding proteins such as multispecific antibodies that bind to at least one transmembrane E3 ubiquitin ligase as well as cell surface proteins intended for degradation.
NSTL
